Immunotherapy in Localized Microsatellite Instability–High/Mismatch Repair Deficient Solid Tumors: Are We Ready for a New Standard of Care?
Mené sur 35 patients atteints d'une tumeur solide de stade avancé ou métastatique et présentant une haute instabilité des microsatellites ou une déficience du système MMR (27 cas de cancer colorectal), cet essai de phase II évalue l'efficacité, du point de vue du taux de réponse complète, et la toxicité du pembrolizumab en traitement néoadjuvant
The hallmark of mismatch repair deficiency is the inability to repair spontaneous mutations during DNA replication, resulting in high tumor mutational burden levels and altered DNA microsatellite sequences or microsatellite instability (MSI).1-3 Although initially this feature was identified as a preliminary screening test for hereditary cancer syndromes such as Lynch syndrome,4 mismatch repair deficiency and MSI have now been recognized as critical predictive biomarkers and define a therapeutic strategy in cancer as well.
Journal of Clinical Oncology , éditorial en libre accès, 2022